The Keck Hospital of USC, formerly USC University Hospital, is a private 401–licensed bed teaching hospital of the University of Southern California.

There are 401 beds in Keck Hospital of Usc.

During the past decade, Keck Hospital of Usc conducted 140 clinical trials. In the 10-year time frame, 140 clinical trials started and 65 clinical trials were completed, i.e. on average, 46.4% percent of trials that started reached the finish line to date. In the past 5 years, 57 clinical trials started and 45 clinical trials were completed. i.e. 78.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Keck Hospital of Usc" #1 sponsor was "University of Southern California" with 29 trials, followed by "Pfizer" with 25 trials sponsored, "Abbott Medical Devices" with 20 trials sponsored, "Medtronic Cardiovascular" with 6 trials sponsored and "Bristol-Myers Squibb" with 6 trials sponsored. Other sponsors include 97 different institutions and companies that sponsored additional 86 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Keck Hospital of Usc" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 5 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "CTI Clinical Trial and Consulting Services" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator and "ICON Clinical Research" with 2 trials as a collaborator. Other collaborators include 84 different institutions and companies that were collaborators in the rest 86 trials.

According to Clinical.Site data, the most researched conditions in "Keck Hospital of Usc" are "Heart Failure" (10 trials), "Pulmonary Arterial Hypertension" (5 trials), "Acromegaly" (4 trials), "Aortic Valve Stenosis" (4 trials) and "Cardiovascular Diseases" (4 trials). Many other conditions were trialed in "Keck Hospital of Usc" in a lesser frequency.

Most popular intervention types in "Keck Hospital of Usc" are "Drug" (91 trials), "Device" (70 trials), "Procedure" (20 trials), "Biological" (12 trials) and "Other" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Cetuximab" (4 trials), "Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)" (4 trials), "Encorafenib" (3 trials) and "Surgical Aortic Valve Replacement (SAVR)" (3 trials). Other intervention names were less common.

The vast majority of trials in "Keck Hospital of Usc" are 177 trials for "All" genders, 7 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 77 active trials in "Keck Hospital of Usc". 2 are not yet recruiting, 43 are recruiting, 30 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 75 completed trials in Keck Hospital of Usc, undefined suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in Keck Hospital of Usc, 14 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 63 trials that are defined as “Not Applicable".

Keck Hospital of Usc has several departments that took part in Clinical trials: "USC Institute of Urology" - 4 trials, "USC Norris Cancer Center; USC Oncology Hematology Newport Beach" - 3 trials, "University of Southern California Keck School of Medicine Memory and Aging Center" - 2 trials, "University of Southern California Adult Comprehensive Epilepsy Center" - 2 trials